Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
New CAR T-cell treatments can ellicit immune-related adverse events, including cytokine release syndrome and neurotoxicity, which require critical care management. We spoke to Élie Azoulay, MD, PhD, of Hôpital Saint-Louis, Paris, France, at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany, about this important emerging area.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.